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Case presentation
A 47-year-old white male was admitted to the Sidney Farber Cancer
Institute (SFCI) for evaluation and treatment of stage IV renal adeno-
carcinoma. In March 1977, the patient experienced gross hematuria
after vigorous exercise. An intravenous pyelogram showed a right renal
mass, and a renal arteriogram demonstrated a vascular mass involving
the middle and right upper pole, A right radical nephrectomy revealed a
renal cell carcinoma measuring 9 x 7 x 8 cm. On histologic examina-
tion, the tumor was moderately well differentiated and of the clear cell
type. No perinephric fat or lymph node involvement was evident, and
the margins of the resected ureter and renal vein were free of tumor.
Evaluation for metastatic disease, including chest x-ray and bone and
liver scans, was negative.
In December 1977, a left pulmonary nodule was observed on chest x-
ray. Roentgenograms in July 1978 revealed multiple pulmonary nodules
in both lung fields and a left hilar lesion. Tomography demonstrated 5
nodules in the right lung fields and 4 nodules in the left lung, each
measuring approximately I x 2 cm.
Physical examination revealed a blood pressure of 130/90 mm Hg.
The remainder of the examination was unremarkable. Laboratory
evaluation included: a normal urinalysis; hemoglobin, 12.9 g; hemato-
crit, 38.4%; white blood cell count, 5600/mm, with 50% granulocytes,
1% bands, 42% lymphocytes, and 7% monocytes. The platelet count
was 218,000/mm3. The BUN was 14 mg/dl; serum creatinine, 1.3 mg/dl;
uric acid, 5.6 mg/dl; and serum glucose, 106 mg/dl. The SGOT was 14
U/liter; LDH, 94 U/liter; and alkaline phosphatase, 3.6 Bodansky units.
The bilirubin was 0.4 mg/dl (direct, 0.1 mg); calcium, 9.7 mg/dl;
phosphorus, 2.7 mg/dl; total protein, 7.6 g/dl; and albumin, 4.64 g/dl. A
workup for metastatic disease confirmed the presence of multiple
pulmonary nodules. Liver and bone scans were within normal limits.
Treatment included combination chemotherapy with vinblastine, 0.1
mg/kg on days 1 and 15, and CCNU [1-(2-chloroethyl)-3-cyclohexyl-1-
nitrosourea (Lomustine)], 120 mg/M2 orally on day 1; this drug
program was administered every 6 weeks. Myelosuppression was mild
during each of the 5 drug cycles the patient received. A chest x-ray after
the fifth cycle revealed an increase in both the number and size of the
pulmonary nodules. In March 1979, therapy was changed to methyl-
glyoxal-bis-guanylhydrazone (methyl-G) at a dose of 500 mg/M2 intrave-
nously once a week for a total of 17 weeks. Although this agent seemed
to stabilize his previously slowing growing pulmonary lesions, new
lesions appeared in the distal left femur, proximal right femur, left
anterior ribs, and left ileum. Complications of the metastatic bony
disease included fracture of his right femoral head, which required
immobilization and surgical pinning, and pain from his left distal
femoral and pelvic lesions; lesions in both femur and pelvis responded
to palliative radiation therapy.
During his recuperation from radiation therapy the pulmonary
lesions again were noted to be enlarging. In March 1980, a subcutane-
ous infusion pump (Infusaid®, Metal Bellows Corporation, Sharon,
Mass.) was inserted for delivery of continuous infusion chemotherapy.
Since that time, the patient has received Adriamycin by continuous
infusion in a dose of 1 to 2 mg/M2/day. He has tolerated this therapy
without complications, and the metastatic lesions in the lung and bone
have not grown further.
Discussion
DR. MARC B. GARNICK (Department of Medicine, Sidney
Farber Cancer Institute, and Assistant Professor of Medicine,
Harvard Medical School, Boston, Mass.): I plan to discuss the
basic biologic aspects of renal cell cancer and the management
of advanced stages of the disease, taking into account new,
investigational therapeutic approaches. My introductory com-
ments will address various aspects of epidemiology, etiology,
pathology, and the myriad of clinical symptoms associated with
renal adenocarcinoma.
The most common cancer arising from the kidney in adults is
renal cell carcinoma (renal adenocarcinoma), which accounts
for approximately 2% to 3% of all new cancers [1]. In 1981, 7000
to 7500 people will die of renal cancer in the United States; this
figure represents 2.3% of male and 1.6% of female cancer
deaths in this country. The incidence of the disease is 7.5 cases
per 100,000 population, and it occurs twice as commonly in
males. Studies indicate that renal cell cancer is somewhat more
common in Scandinavians and North Americans, and that the
incidence is distinctly lower in Asians and Africans. Most
patients are found to have the disease when they are between 55
and 60 years old. A moderate association between tobacco use
and the incidence of renal cell carcinoma has been found [2],
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Hematuria (usually painless,
total)
Flank pain
Renal mass
Acute varicocele
A-V fistulae (may be
associated with high-output
CHF)
Hypertension
Malaise, weight loss, anemia
Fever (in association with
other abnormalities)
Fever (as sole presenting
feature)
Abnormal, nonmetastatic 0—12
liver chemistries
Amyloidosis 4
Neuromyopathy 4
Erythrocytosis (2°) 4
Elevated ESR 50
Hypertension (renin- (CR)
mediated)
Hypercalcemia (PTH- (CR)
mediated)
Enteropathy (2° to glucagon) (CR)
Others: prolactin, (CR)
prostaglandins
11-year history of abdominal mass with history
of polycystic kidney
Chest pain, dyspnea, 2° to RCCC blocking IVC
Calcific renal mass in patient with 12-year
history of breast cancer
Immune complex glomerulonephritis
Renal hemorrhage following anticoagulation for
an MI
and a variety of chemical and biologic agents have produced
renal tumors in animals. These agents include lead phosphate,
dimethylnitrosamine, prolonged estrogen administration to
male hamsters, aflatoxin B 1, viral infections in leopard frogs [2—
51, and streptozotocin [6—11]. No conclusive evidence has
established a causative link to renal cell carcinoma in humans,
although preliminary work has indicated a potentially higher
risk in cadmium workers who smoke [12]. Von Hippel-Lindau
disease, which is transmitted in an autosomal dominant fashion,
is associated with retinal angiomas and hemangioblastomas of
the central nervous system and might be associated with renal
cell carcinoma [13]. Most recently, a constitutional chromo-
somal translocation between chromosomes 3 and 8 has been
found in a kindred, many of whom had advanced renal carcino-
ma. If abnormal chromosomes can be used as markers, family
members at risk can be screened at an early, asymptomatic
stage [14].
Pathology. The subtypes of renal adenocarcinoma include
clear cell, granular cell, and spindle tumors. The term "hyper-
nephroma," introduced at the turn of the century, arose from
the belief that these tumors developed from adrenal rests. Most
Table 2. Chemotherapeutic and hormonal agents used in treating
advanced renal cell carcinoma
Number
Agent
of
patients
Response
rate (%)
Hormonal agents
Progestational agents (PA) 695 5
Adrogenic agents 190 3
Single agents
CCNU 79 10
MeCCNUb 45 4
Cyclophosphamide 132 9
Hydroxyurea 140 Il
5-Fluorouracil 201 5
Vinbiastine (VBL) 296 16
Adriamycin (ADR) 65 0
Methyl-G° 25 16
Cis-platinum 60 0
Combination therapy
VBL + CCNU 29 24
VBL+PA 38 8
VBL + MeCCNU 38 10
MeCCNU + PA 38 10
ADR + vincristine + PA + BCOd 31 33
CCNU refers to 1-(2 chloroethyl)-3-cyclohexyl-1 -nitrosourea
(Lomustine®)
bMeCCNU refers to methyl l-(2 chloroethyl)-3-cyclohexyl-l-nitro-
sourea (Carmustine)
cMethylG refers to methylglyoxal-bis-guanylhydrazone
dBCG refers to bacillus Calmette-Guérin
current immunohistochemical, fluorescent, and light and elec-
tron microscopic evidence indicates that renal adenocarcinoma
originates from the tubular epithelium U, 15]. Hence, "hyper-
nephroma" is not an appropriate term and should be aban-
doned. What is intriguing both from the clinical and pathologic
standpoint is whether renal adenoma is a precursor of renal cell
carcinoma. Some evidence suggests that renal cell carcinoma
can develop after a progressive series of metaplastic and
neoplastic changes, including adenomatous hyperplasia [16].
Clinical presentations. Table 1 includes the most common
clinical features of patients with renal adenocarcinoma. Renal
adenocarcinoma has been dubbed the "internist's tumor,"
because signs and symptoms rarely indicate a renal abnormali-
ty. Earliest complaints usually include weakness, weight loss,
and anemia, and these occur in approximately one-third of
patients. The diagnostic triad of hematuria, flank pain, and
palpable mass occur in only 10% to 12% and signify metastatic
disease in approximately 50% of patients who present in this
manner. Overall, approximately one-third of patients have
metastatic disease at initial examination.
The staging characteristics of renal carcinoma are schemati-
cally depicted in Figure 1. Stage I indicates that the tumor is
confined to the renal parenchyma; stage II involves perinephric
fat, but usually is confined to Gerota's fascia; stage III affects
regional lymph nodes, with or without renal vein or inferior
vena cava involvement; and stage IV disease includes involve-
ment of adjacent organs, distant metastatic disease, or both at
initial presentation. Common sites of metastatic disease include
the lung (usually endobronchus), bone, brain, thyroid, adrenal
gland, colon, spleen, diaphragm, and liver.
The time from initial examination to presentation of metastat-
ic disease can be a good predictor of survival. If metastases are
detected longer than one year after the original diagnosis of
Table 1. Clinical features of renal adenocarcinoma
Feature Incidence (%)
40
50
30
3
Rare
Common
(equal to
incidence
for age
group)
33
17
2
1. Local
2. Systemic/
paraneoplastic
3. Other unusual
presentationst'
Case reports
bData from Ref. 19
CRCC refers to renal cell carcinoma
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Fig. 1. Staging and 5- and 10-year survival charac-
teristics of 309 patients with renal adenocarcinoma
treated with nephrectomy (from Ref. 18).
Stage I — 102 patients
Stage Ill — 108 patients
5 yr = 65%
10 yr = 56%
5 yr 51%
10 yr 37%
Stage II — 22 patients
Stage IV — 77 patients
Plus: distant metastases
or extension to contiguous
visceral structures
5 yr47%
20%
5 yr 8%
10 yr = 7%
renal adenocarcinoma has been established, and the lesions are
either solitary or in accessible areas, surgical resection should
be attempted [171. If, however, metastatic disease develops
within one year following original diagnosis, the low probability
of lengthening survival time does not warrant an extensive
surgical approach. The poor prognosis of advanced stage IV
patients is illustrated in Figure 1, which is based on a large
surgical series in which the overall survivorship of patients with
stage IV, that is, metastatic disease, is quite low: the median
survival of patients with advanced disease is approximately 12
months [18].
Several recent review articles have examined the clinical
presentation of the disease [19—21]. Aspects of diagnostic
evaluation, including radiologic and arteriographic procedures,
primary and specialized surgical resections, and arterial emboli-
zation techniques, which constitute the initial management in
patients without metastatic disease, have been reviewed in
numerous articles [1, 22—27].
Management of patients with advanced disease. Optimal
management for the patient with advanced disease such as the
man presented today should employ a multidisciplinary ap-
proach involving urologic and thoracic surgeons, medical on-
cologists, and radiation therapists. A combined modality ap-
proach is most likely to improve the potential response of this
lesion; combined medical and surgical therapies can most
effectively manage the paraneoplastic and other unusual clinical
symptoms and findings [19—21, 28—32]. Unfortunately, the
majority of patients with advanced renal adenocarcinoma do
not have resectable disease. Until the present, the management
of patients with advanced renal adenocarcinoma has been one
of the more frustrating areas in medical oncology, and most
centers treating these patients have employed investigational
therapeutic approaches. Table 2 shows various hormones,
chemotherapeutic agents, and combination therapies that have
been used in treating advanced renal cell carcinoma. These
treatment modalities will be discussed further.
Surgery has a dual role in the management of patients with
stage IV renal adenocarcinoma. First, surgical removal of the
involved kidney may be required in patients who have fever,
pain, infection, or other local symptoms resulting from the renal
tumor itself. Surgical removal is performed in this setting solely
for palliative, not curative, reasons. The second surgical role
involves pulmonary "nodulectomy" in patients who present
initially with a renal adenocarcinoma, and who later develop
pulmonary metastatic disease, as did the patient discussed
today. This same approach has been used for surgical removal
of isolated brain metastases. Katzenstein et al recently re-
viewed the role of pulmonary resection for metastatic renal
adenocarcinoma in 44 patients [33]. These data suggest that
surgery is a valuable treatment for unilateral pulmonary metas-
tases. In a group of 20 patients in whom lung metastases
developed 0 to 120 months after renal carcinoma was diag-
nosed, a distinct survival advantage was found in the patients
who had solitary lesions on x-ray. The mean survival of these
patients was 38 months, compared to a 2.5-month mean surviv-
al in patients in whom bilateral lesions were detected.
The use of hormonal therapy for renal cell carcinoma orig-
inally was based on the observation that the administration of
diethylstilbestrol to male golden Syrian hamsters induced ade-
nocarcinomas of the kidney [34]. The growth of these tumors
was diminished when either testosterone or progestational
agents were administered with the diethylstilbestrol. Although
original clinical data suggesting a response rate close to 20%
have been reported by several investigators [35—37], most
patients do not respond adequately to hormonal manipulation.
Poor experimental design in several studies, including a lack of
controls and varying selection criteria, account for the difficulty
in reproducing response rates associated with hormonal thera-
pies [38]. More recently, however, Concolino et al found both
estradiol and progesterone receptors from the cytosol fraction
of renal adenocarcinomas in 23 patients [39]. Estrogen recep-
tors were found in 61% and progesterone receptors in 61% of
the carcinomas studied, whereas 39% of the tumors were
positive for both estradiol and progesterone; 17% were negative
for both. The effect of progestational or androgenic therapy was
then assessed and related to the estrogen and progesterone
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receptor activity of the primary renal cancer. Six of 9 patients
who were receptor positive for both hormones demonstrated a
therapeutic effect; 4 of 5 patients with estradiol positivity and
progesterone negativity had temporary control of their cancers,
as did 3 of 5 patients whose response to estradiol was negative
and whose response to progesterone was positive; of 4 patients
who responded negatively to both hormones, only one had a
good therapeutic result. However, many of these patients were
being treated after nephrectomy with adjuvant hormonal thera-
py based on the receptor states of the lesions. Hence, a rational
application of hormonal therapies in the future might be predi-
cated on the receptor status of renal adenocarcinomas.
In two related studies using the antiestrogen tamoxifen, no
objective responses were noted [40, 411. In 148 patients treated
with antiestrogens, an overall response rate of 7.4% was
demonstrated.
Table 2 includes single drugs and combinations of chemother-
apeutic agents that are used with or without hormonal or
immunologic adjuncts [36, 38, 42—51]. Initial data in patients
with stage IV renal adenocarcinoma revealed that the combina-
tion of vinblastine plus the nitrosourea CCNU yielded a 7%
complete remission rate; 24% of the patients had a complete or
partial response, with survival being longer in patients who
experienced a response [42].
I will focus next on several other innovative chemotherapeu-
tic approaches that we have used at the SFCI in managing
patients who have advanced renal adenocarcinoma. A recent
observation from the Southwest Oncology Group indicated that
the use of methyl-G (methylglyoxal-bis-guanylhydrazone), a
compound initially synthesized in 1958 and extensively tested in
leukemia patients in the 1960s, benefited patients who had
genitourinary cancers, including clear cell adenocarcinoma of
the kidney [52]. The mechanism of action is related to its potent
inhibition of polyamine synthesis [53—57]. Specifically, at mi-
cromolar concentrations, methyl-G inhibits the enzyme 5-
adenosyl-L-methionine-decarboxylase, which blocks the syn-
thesis of spermidine and spermine from putrescine, polyamines
which appear to have an important regulatory role in DNA and
RNA metabolism (Fig. 2). These observations have been noted
in in vitro experiments with activated lymphocytes, as well as in
the Ll2lO leukemia murine and human HeLa cell systems. In
the latter system, the addition of methyl-G to HeLa cell cultures
resulted in increased putrescine levels and decreased spermi-
dine and spermine levels; these changes were followed by a
decline in the incorporation of tritiated thymidine, uridine, and
'4C leucine. Simultaneous administration of all polyamines and
methyl-G prevented this inhibition. In studies using synchro-
nized cells to determine whether inhibition was phase specific,
researchers observed that whereas spermidine and spermine
were not essential during the S. G, or mitotic phases, subopti-
mal polyamine levels resulted in a general decrease in the rate at
which cells proceed through cell cycle [56, 57]. Further experi-
ments suggested that inhibition of DNA synthesis by methyl-G
is mainly due to a reduction in the number of active replication
units per cell, and that this finding is consistent with the theory
that initiation of new replication units depends in some way on
the concentration of spermidine and spermine [56]. Because
urinary and serum polyamine levels have been directly correlat-
ed with tumor burden in individuals with cancer, a causal
c
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Fig. 2. The metabolic pathway of potvamine biosynthesis. SAM refers
to S-adenosyl-L-methionine.
relationship between polyamine levels and rapidly replicating
cells has been suspected [58]. At higher concentrations (over
100 micromolar), methyl-G has other toxic effects on cellular
metabolism, including inhibition of both mitochondrial respira-
tion [59] and protein synthesis [55].
A Minnesota group has developed an in vitro model for
assessing potential drug efficacy in human renal cell cancer [60].
The model is based on the release of polyamines and 125j UDR
(5-iodi-2'deoxyuridine) into cell culture medium by renal neo-
plastic cells as they undergo cell death. The release of poly-
amine and 1251 UDR into the medium is inversely related to
cellular growth. During lag and growth phases, the release of
polyamines into the tissue culture medium increases gradually.
With eventual cell death and lack of cell renewal, both levels
markedly increase in the medium. The authors are currently
investigating various chemotherapeutic agents that they expect
will cause an increase in polyamines in the culture medium if
cell death results. These experiments might help explain the
potential usefulness of methyl-G in patients with renal cancer.
The use of methyl-G has been evaluated extensively in
patients with advanced renal carcinoma at the SFCI [61].
Twenty-five patients with measurable disease received intrave-
nous methyl-G weekly at a starting dose of 500 mg/M2, with
dose escalations of 50 mgIM2/week (maximum dose, 900 mg/M2/
week). Of the 25 patients, 4(16%) achieved responses; of these,
3 patients partially responded and 1 completely responded. The
median response duration was 9 weeks (range, 4 to 15 weeks).
Nine patients (36%) remained stable, and 12 (48%) had progres-
sive disease. In the patients who responded, regression of
disease occurred within the first 4 weeks of therapy. The side
effects were generally mild and included nausea and vomiting,
neuromyalgias, weight loss, and less frequently, diarrhea. Leu-
kopenia was not observed at this dose schedule. The potential
now exists for the combination of methyl-G, which does not
Putrescine
NH3— CH2—CH2—CH2—CH2—NH3
NH3—(CH214---NH2—(CH2)3—NH3
Spermidine
Decarboxylation
& propylamine
transfer
(CH2)3-NH3
from SAM
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Fig. 3. Idealized cell cycle model of an individual tumor cell (from Ref.
62). G refers to the postmitotic phase; S refers to the DNA synthetic
phase; and 02 refers to a postsynthetic phase.
have myelosuppressive side effects when used in this weekly
schedule, with other myelosuppressive drugs such as vinbias-
tine or CCNU; these data are very preliminary, however, and
should be interpreted cautiously.
Optimizing chemotherapeutic drug schedules using the prin-
ciples of cell kinetics is another recent approach we have used
in managing patients with advanced renal cell cancer. Figure 3
illustrates an idealized cell cycle model of an individual tumor
cell [621. Cellular division occurs during the mitotic phase (M).
Post-mitotic phase (G1) represents the time interval when RNA
and protein synthesis continue in variable duration and length.
Cells in G1 can either traverse the remainder of the cell cycle or
enter a quiescent resting phase (G0). The DNA synthetic phase
(S), is usually less variable in length and ranges between 10 and
24 hours. Phase G2 follows S; the cell at this period possesses a
diploid number of chromosomes and two times the DNA
content. Information gained from tritiated thymidine labeling
techniques indicates that most human tumor cells possess a
generation time (Ta, the time to traverse the cell cycle) in the
range of 2 to 5 days. If G1 is long, the cell remains in a resting
stage, but it usually maintains the capacity to proliferate.
Although cellular T is between 2 and 5 days, the actual
doubling time for renal tumor volume is far longer than this,
usually averaging 100 days. One explanation for this difference
between the short cell generation time and the actual tumor
volume doubling time is that the growth fraction, defined as the
ratio of cells in cycle to the total number of cancerous cells [63],
usually decreases as the tumor increases in size. In addition,
cell loss, the rate of which is derived from the difference
Table 3. Cytokinetics of renal cell cancer
Parameter Time (median)
T 37 hours
T01
T5
10 hours
17 hours
T0, 3 hours
GFb 0.03
DT(a)C 100 daysT 154
DT(p)" = = = 51 days
DT()CU = 1 - — =
DT(a)
50 %
aT refers to generation time
bGF refers to growth fraction
CDT(a) refers to actual doubling time
dDT(p) refers to potential doubling time
CL refers to cell loss
between the potential tumor doubling time and the actual tumor
doubling time [64], contributes to the difference (see Table 3).
These concepts have allowed investigators to examine the
cellular kinetics of renal adenocarcinoma (Table 3). Using data
by Rabes et al [65] and employing the principles of cellular
kinetics proposed by Shirakawa et a! [66], one can extrapolate
that the T for renal cell cancer approximates 37 hours, with a
TG1 of 16 hours, a T5 of 17 hours, and a TG2 of 3 hours. The
growth fraction has been estimated to be approximately 3%.
The actual tumor doubling time in the patient under discussion
was 100 days; the potential tumor doubling time has been
estimated to be 50 days; on this basis, the cell loss can be
estimated to be 50% (Table 3). Given that the actual tumor
doubling time of the patient under discussion today is in the
range of 100 to 110 days (based on serial chest roentgenograms),
therapies administered on an intermittent or "pulse" basis
would not uniformly expose noncycling cancer cells to thera-
peutic concentrations of the anticancer agent. We, therefore,
have begun to use continuous infusions in such patients.
The concept of continuous infusion of antineoplastic therapy,
in fact, has many rationales. From a kinetic point of view, the
flux of cells in and out of cycle for low-growth-fraction tumors
is extraordinarily low. Recent techniques used to characterize
the cellular kinetics of renal adenocarcinomas as described
above indicate that the labeling index ranges between 0.6% and
3.0% [65]. The labeling index indicates that fraction of cells
within a population that retains the label following a dose of
tritiated thymidine and usually indicates the fraction of cells in
S phase. Again, there is a large nonproliferating compartment of
cells and a great deal of proliferative heterogeneity in advanced
human cancers. From a biochemical standpoint, drugs such as
Adriamycin preferentially bind to DNA during the S period [62.
67, 68]. Recent experimental work indicates that there is a
large, nonproliferating compartment of cells that might intermit-
tently enter cell cycle, but the drug would not be effective if the
cells were in G0 or resting phase. Animal studies indicate that in
rapidly growing lymphoblastic tumors, intermittent intensive
administration of chemotherapy yields a superior response to
treatment [69], whereas in cancers in which the growth fraction
ADA dose 0.2
(mg/kg/day) 0.1
0
(Xt)
_____________________
0 1 2 3 4 5 6 7 8 9 1011 12
is low, continuous therapy usually offers better results [70].
Preliminary studies in humans have shown that this latter
method enhances the response rate of patients with metastatic
breast carcinoma, a cancer with a long tumor-doubling time
[71]. The patients were given cyclophosphamide, methotrexate,
5-fluorouracil, vincristine, and prednisone; continuous adminis-
tration of these drugs produced a superior objective response
rate than did giving the same agents on an intermittent schedule
[71]. Finally, from a toxicologic standpoint, continuous infu-
sion, low-dose therapy might be less toxic for certain drugs
such as Adriamycin if the drug can be administered safely and
conveniently on a continuous basis [73, 74].
The development of a totally implantable subcutaneous infu-
sion pump [74—76] (Infusaid®, Metal Bellows Corporation,
Sharon, Mass.) has enabled the continuous infusion of systemic
chemotherapy, specifically Adriamycin [77, 78]. The apparatus
already has been employed clinically for several years for
continuous intravenous infusion of heparin. The pump, a disk-
shaped device 3 inches in diameter, is implanted in the infracla-
vicular region, where a Silastic catheter emanating from the
pump is placed in the subclavian vein. The pump is minimally
disfiguring, and when in place it looks like a cardiac pacemaker.
Its drug chamber capacity is approximately 50 ml. The rate of
drug delivery is controlled by a stainless steel flow restnctor
(Fig. 4). The titanium metal bellows is powered by a fluorocar-
bon which, at 37° C, is in equilibrium with its vapor phase; the
vapor maintains almost constant pressure against the metal
bellows, even as the chamber volume changes. The pump is
resupplied with drug via a needle placed through the skin and
then through a rubber septum that connects with the metal
bellows chamber. The pump allows continuous infusion of
chemotherapeutic agents over months. We have implanted the
pump in several patients including the man discussed today. His
disease has remained stable for several months after implanta-
tion of the pump.
Pharmacologic work has accompanied the clinical studies of
the continuous infusion of Adriamycin, both on a clinical and
preclinical level. In one long-term animal study (Fig. 5), a
beagle, implanted with a metal bellows pump, received 0.08 mgI
kg/day to 0.2 mg/kg/day of Adriamycin (personal observations).
White blood cell count, platelet count, blood chemistries, and
pharmacologic levels of Adriamycin were monitored during the
12 weeks of the study. Myelosuppression was first noted at a
dose of approximately 0.15 mg/kg/day, at which point Adriamy-
cm plasma levels were detectable. As the dose was increased,
correspondingly higher plasma levels of Adriamycin and lower
white blood cell and platelet counts were observed. These
studies have been extended to the clinical situation and should
allow the dose of this drug to be modulated in accordance with
clinical toxicity and blood levels [77, 78]. The use of continu-
ously administered chemotherapy seems particularly well suit-
ed for many cancers that exhibit growth characteristics similar
to those of renal adenocarcinoma.
Immunotherapy for renal cell cancer. Several investigators
have used immunotherapy to treat patients who have advanced
renal cell carcinoma [79, 80]. Steele et al used xenogeneic
immune RNA to treat 6 patients who had advanced renal cell
cancer; the RNA was extracted from the lymphatic tissue of
guinea pigs previously implanted with a specimen of the pa-
tient's renal cell cancer obtained at nephrectomy [81]. Tumor
regression occurred in 50% of the patients. Parallel laboratory
investigations have demonstrated enhanced in vitro lymphocyte-
mediated cytolysis against allogeneic renal cell carcinoma
targets following immunotherapy [82]. Much more work needs
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Inlet septum
Bellows
Charging fluid chamber
Drug chamber
Fig. 4. Cross-sectional diagram of the totally implan-
table, subcutaneous infusion pump (Infusaid® model
100).
Weeks
Fig. 5. Hematologic and pharmacologic characteristics of continuous
infusion Adriamycin (ADR) in a beagle dog. A refers to an open wound
and the initiation of antibiotic therapy; B indicates when the pump was
removed.
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to be done in this novel method of treating renal cell carcinoma
before its efficacy can be evaluated.
To date, there has been no single, uniformly effective treat-
ment for patients with stage IV renal cell carcinoma. While
there may be some potential clues based on today's discussion,
these approaches are totally investigational and underscore the
necessity for protocol studies using existing agents in a novel
fashion or employing new agents. Nearly all comprehensive
cancer centers are studying new approaches for patients with
renal cancer. Hopefully, these efforts will hasten progress in
our treatment of the disease.
Questions and answers
Da. DOUGLAS TAYLOR (Oncology Fellow, NEMC): Do you
advocate nephrectomy in patients with renal adenocarcinoma
when the tumor is known to have invaded the inferior vena
cava? And what is the best staging test for detecting IVC
involvement?
Dg. GARNICK: Absolutely. Surgery remains the optimal treat-
ment in patients who have invasion of the inferior vena cava but
who do not have distant metastases, that is, patients who do not
have stage IV disease. Preoperative staging with inferior vena
cavography has become a valuable and necessary part in
planning the operation [83, 84]. Surgical removal of tumor
extending into the right atrium can be accomplished [85]. In
response to your second question, a recent report has critically
examined CT scanning and angiography in evaluating renal
cancer: CT was more accurate and sensitive than was angiogra-
phy in detecting perinephnc extension and was equally accurate
in assessing main renal vein and venal caval involvement [86].
This experience suggests that preoperative angiography per-
haps should not be performed routinely as a diagnostic study
and may be necessary only under certain circumstances, for
example, when the CT scan is equivocal.
DR. ANDREW LEVEY (Renal Fellow, NEMC): Now that we
can administer drugs continuously, would you review in more
detail the cytokinetic and biochemical rationale for using con-
tinuous infusion therapy?
DR. GARNICK: Most agents are more active against replicat-
ing, as compared to resting, tumor cells. Since the growth
fraction of most macroscopic human solid tumors is less than
10%, such chemotherapeutic agents, most of which have a
relatively short bioavailability time, would not be expected to
be active against such tumors when given intermittently, such
as every 3 to 4 weeks. However, since tumor cells flux into and
out of proliferative cycle, the continuous presence of a chemo-
therapeutic agent might be expected to be more effective [67].
Adnamycin and other agents that inhibit DNA polymerase
activity are substantially more active in vitro during the S
period [69, 70]. As explained earlier, this would support the
potential superiority of continuous, as compared to intermit-
tent, drug administration schedules [67].
For high-growth-fraction tumors, such as L1210 and most of
the experimental, transplantable tumors, drug schedule sensi-
tivity varies depending on the drug and the tumor. Cyclophos-
phamide is more active when given intermittently against early
L1210, whereas continuous administration is more effective
against advanced L12l0 [87]. The commonly employed trans-
planted experimental solid tumors include the B16 melanoma,
the Lewis lung, the C3H breast, and the colon 26 carcinoma.
Studies of the schedule of drug administration against such
tumors generally indicate that the more cell-cycle-specific the
agent, the greater the effectiveness when given daily as com-
pared to intermittently, for example, every 4 or 7 days [87].
However, it should be emphasized that the growth fraction of
these tumors is at least 50% [68, 69, 87], the growth rate is
relatively rapid, and from the cytokinetic viewpoint at least,
these models are not particularly good experimental counter-
parts for human solid tumors in which the growth fractions are
commonly less than 20%.
DR. JORDAN J. COHEN: In the kinetic model of tumor growth
that you discussed, you used the term "cell loss" and indicated
that as many as one-half of the cells in a particular tumor were
"lost." Does that mean that they actually died after mitosis or
that they were just lying dormant?
DR. GARNICK: The term "cell loss" embraces both cell death
and cells that are temporarily non-dividing. These latter cells
can revert to dividing cancer cells, or they can become perma-
nently non-dividing cells that eventually will die.
DR. COHEN: Do you mean some cells in a cancer are not
cancerous?
DR. GARNICIC: Cytokinetically, there are some cells within a
cancer that are in prolonged G0. It becomes a semantic differ-
ence whether you want to call these cells cancerous. Many
investigators in the field of cytokinetics believe that for a cell to
be called cancer it cannot remain permanently in G0. It must be
an obligate replicator.
DR. JOHN T. HARRINGTON: What is your opinion about the
usefulness of urinary cytology in patients with renal carcinoma?
DR. GARNICK: The usefulness of urinary cytology in renal cell
cancer is limited. Only 7% or 8% of renal cancers will have
eroded through the calyx prior to presentation. Thus, urinary
cytology is positive in a very small proportion of patients with
renal cancer.
DR. KENNETH MILLER (Staff Hematologist/Oncologist,
NEMC): Would you comment on the familial incidence of renal
cell carcinoma?
DR. GARNICK: There have been several instances of patients
with primary renal cancer within the same family [88]. Howev-
er, this is unusual in the absence of an association with Von
Hippel-Lindau's disease [89]. Cohen et al recently described
renal cancer in 10 members of three consecutive generations
[14]. As I mentioned previously, karyotypes demonstrated a
balanced reciprocal translocation between chromosomes 3 and
8.
DR. COHEN: Is the familial form of the disease sufficiently
prevalent to justify routine family screening whenever the
diagnosis of renal cell cancer is made?
DR. GARNICK: Our ability to identify genetically related
cancers might allow earlier diagnosis, but familial forms are
rare. Members of our Institute are, however, screening patients
who develop a renal cancer while relatively young, that is, less
than 35 years of age, as well as families in which more than 2
members are affected with the disease. We also investigate the
patient's family if the patient has bilateral renal cancers.
Whether earlier diagnosis will lead to cure or improved survival
is still speculative at this point.
DR. DONALD HRICIK (Renal Fellow, NEMC): What is your
present recommendation regarding the use of hormonal therapy
in advanced renal cell carcinoma?
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DR. GARNICK: I believe that there is little, if any, role for
hormonal therapy in advanced renal cancer. After studying
more than 600 patients, Hrushesky and Murphy reported an
overall response rate of only 2% to 5% [361. We are not,
therefore, likely to learn anything by treating patients with
relatively ineffective hormonal therapy on an ad hoc basis. If
appropriate, however, patients with advanced forms of disease
should be entered into prospective phase II (activity-seeking)
and phase III (comparative) trials with investigational ap-
proaches. There might be a subset of patients with renal cancer
whose tumors will respond to a hormonal maneuver that is
based on the receptor status of the cancer. I would advocate
hormonal therapies such as antiandrogens or progestational
agents in well-designed prospective trials based on receptor
status of the primary or metastatic lesions.
DR. COHEN: On what basis do you determine that renal cell
cancer originates in the proximal tubular epithelium?
DR. GARNICK: Electron microscopic findings of renal adeno-
carcinomas have demonstrated that the neoplastic cells most
resemble proximal tubular epithelial cells and are distinctly
unlike those of the glomerulus, the loop of Henle, or the distal
convoluted or collecting tubule [15, 16, 90]. The electron
microscopic features of renal adenocarcinoma and proximal
tubular epithelium include similarities in microvilli and brush
border structure, pinocytotic vesicles, plasma membrane in-
foldings, and mitochondria structure. Bennington recently re-
viewed these similarities and the relationship between adenoma
and carcinoma [90].
DR. COHEN: What is the relationship of renal cell carcinoma
to adenoma, and is the size of the initial tumor related to the
prognosis of the disease? Such a relationship might be anticipat-
ed if tumor growth rate is an important variable.
DR. GARNICK: The relationship between renal adenoma and
carcinoma is somewhat controversial, as ultrastructural studies
have shown that both seem to arise from the proximal tubular
epithelium. Both have been associated with tobacco use, and
both arise in the same age group. The distinction between
adenoma and adenocarcinoma is important, as adenomas are
commonly found at autopsy in patients with and without known
renal cancer. In one series, adenoma size was used as a
criterion of malignant potential: tumors less than 3 cm in
diameter were infrequently associated with metastases, where-
as those larger than 3 cm were more commonly associated with
metastatic disease [91]. Size of the primary does not have
independent prognostic significance in patients who present
with stage IV disease. However, there is a greater likelihood of
a patient having either stage II or III disease at presentation if
the lesion is large and has invaded vascular or lymphatic
structures.
DR. COHEN: What is the role of ultrasonography in differenti-
ating a benign renal cyst from a solid tumor? Do you think that
arteriography is mandatory to determine whether such a mass is
benign or malignant?
DR. GARNICK: Ultrasound scanning has improved our ability
to differentiate between a benign simple cyst and a tumor [92].
In one series, ultrasound usage had a sensitivity and specificity
of 97% and a false-negative rate of only 1% in 413 patients [93].
When both nephrotomography and ultrasonography indicate
that a lesion is a benign cyst, an accuracy rate of 97% to 98%
can be expected. Although a renal cancer can coexist within a
kidney that contains a simple serous cyst, the incidence is rare
[94].
DR. COHEN: Is there a role for cyst aspiration in differentiat-
ing benign from potentially malignant lesions?
DR. GARNICK: If the nephrotomographic and ultrasonic ex-
aminations raise any suspicion regarding a cystic mass, or if one
desires to increase diagnostic accuracy beyond 97%, a cyst
puncture, performed percutaneously, can be done under ultra-
sonic guidance. The aspirated fluid should be analyzed for
cytology, fat, and lactate dehydrogenase; contrast material also
can be instilled. If the aspirate is bloody, renal cancer should be
high in the differential diagnosis [95]. Because renal cysts are so
common in patients over 50 years old, reasonable criteria
should be established regarding when to initiate invasive diag-
nostic procedures. Cyst puncture is probably an unnecessary
procedure in totally asymptomatic patients who demonstrate a
classic benign cyst in nephrotomography and ultrasonography.
However, if any suspicious finding such as hematuria is present
or if the ultrasonic evaluation demonstrates internal echoes,
further diagnostic testing with either CT scan or arteriography
is indicated.
Reprint requests to Dr. Marc B. Garnick, Sidney Farber Cancer
Institute, 44 Binney Street, Boston, Massachusetts 02115, USA.
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